COH 29Alternative Names: COH-29
Latest Information Update: 27 Jun 2016
At a glance
- Originator City of Hope National Medical Center; Novonco Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Ribonucleotide reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Leukaemia